ImmunityBio, Inc. Operating Income Loss

• ImmunityBio, Inc. showed an increase of +25.6% in Operating Income Loss from 2024 to 2025.
• This data is from ImmunityBio, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
• XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 12 years of available data (2014 to 2025), ImmunityBio, Inc.'s Operating Income Loss has declined by 4,492.4%.
• Historical annual values: Fiscal year 2025: -$256.03 million | Fiscal year 2024: -$344.18 million | Fiscal year 2023: -$362.25 million | Fiscal year 2022: -$351.30 million | Fiscal year 2021: -$330.28 million | Fiscal year 2020: -$220.88 million | Fiscal year 2019: -$156.25 million | Fiscal year 2018: -$98.39 million | Fiscal year 2017: -$99.12 million | Fiscal year 2016: -$124.50 million | Fiscal year 2015: -$238.88 million | Fiscal year 2014: -$5.58 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026